Download PDF
Onkologische Welt 2010; 01(04): 167-168
DOI: 10.1055/s-0038-1632836
Neuro-Onkologie
Schattauer GmbH

Hirntumortherapie

Ein UpdateBrain tumour therapyAn update
H. Link
1   Medizinische Klinik I, Hämatologie und Onkologie, Westpfalz-Klinikum Kaiserslautern
,
R. Fink
2   Neurologische Klinik, Westpfalz-Klinikum Kaiserslautern
› Author Affiliations
Further Information

Publication History

Eingegangen am: 31 August 2009

angenommen am: 02 September 2009

Publication Date:
03 February 2018 (online)

    Permissions and Reprints

Zusammenfassung

Die Therapie der primären Hirntumoren erfährt derzeit einen neuen Schub durch dia-gnostisch und therapeutisch relevante Erkenntnisse im molekularen Bereich. Es werden Defekte der Wachstumsregulation definiert, die in ähnlicher Form auch bei anderen malignen Erkrankungen vorkommen. Gegen diese definierten Defekte werden immer mehr zielgerichtete Therapien mit spezifischen Hemmstoffen verfügbar. Dadurch eröffnen sich neue Perspektiven, die Therapie zu verbessern.

Summary

Therapy of primary brain tumours gets a new impact by new insights into the molecular mechanisms of disturbed cell growth. It is possible, to define specific defects of cellular signal transduction cascades, which often use similar in other malignant tumours. Thus specific inhibitors available for other tumours may also be applied in gliomas providing new therapeutic options.

Schlüsselwörter

Gliome - Chemotherapie - molekulare Diagnostik - zielgerichtete Therapie

Keywords

Glioma - chemotherapy - molecular diagnostic - targeted therapy
 

  • Literatur

  • 1 Barnholtz-Sloan JS. et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveil-lance System. J Clin Oncol 2004; 22: 2865-72.
    CrossrefPubMedGoogle Scholar
  • 2 Braus DF. et al. Primary cerebral malignant nonHodgkin‘s lymphomas: a retrospective clinical study. J Neurol 1992; 239: 17-24.
    Google Scholar
  • 3 Cloughesy TF. et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol (Meeting Abstracts) 2008; 26: 2010.
    CrossrefGoogle Scholar
  • 4 Delattre JY. et al. Distribution of brain metastases. Arch Neurol 1988; 45: 741-4.
    CrossrefPubMedGoogle Scholar
  • 5 Hegi ME. et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N Engl J Med 2005; 352: 997-1003.
    CrossrefPubMedGoogle Scholar
  • 6 Mohile NA, Abrey LE. Primary central nervous system lymphoma. Neurol Clin 2007; 25: 1193-207.
    CrossrefPubMedGoogle Scholar
  • 7 Sanai N, varez-Buylla A, Berger MS. Neural Stem Cells and the Origin of Gliomas. N Engl J Med 2005; 353: 811-22.
    CrossrefPubMedGoogle Scholar
  • 8 Stupp R. et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 2005; 352: 987-96.
    CrossrefPubMedGoogle Scholar
  • 9 Vredenburgh JJ. et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25 (Suppl. 30) 4722-9.
    CrossrefPubMedGoogle Scholar
  • 10 Walker MD. et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49: 333-43.
    CrossrefPubMedGoogle Scholar
  • 11 Weil RJ. Incorporating Molecular Tools into Early-Stage Clinical Trials. PLoS Med 2008; 5: e21.
    CrossrefPubMedGoogle Scholar
  • 12 Wen PY, Kesari S. Malignant Gliomas in Adults. N Engl J Med 2008; 359: 492-507.
    CrossrefPubMedGoogle Scholar
  • 13 Yan H. et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360 (Suppl. 08) 765-73.
    CrossrefPubMedGoogle Scholar